Clinical Trial Update: A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-5817 Injection [Phase 1]

View source ↗

Summary

Phase I study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-5817 injection in obesity/overweight; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• HRS-5817

Snippet

Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. | Conditions: Obesity, Overweight | Phase 1 | Status: RECRUITING